Trials / Not Yet Recruiting
Not Yet RecruitingNCT05640726
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-1 | Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks |
| RADIATION | SCRT | Radiotherapy dose: 5×5 Gy |
| DRUG | Bevacizumab | Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks |
| DRUG | Oxaliplatin | Participants will receive Oxaliplatin，85mg/m2，day1 |
| DRUG | Calcium folinate | Participants will receive calcium folinate ，400mg/m2，day1 |
| DRUG | 5-fluorouracil | Participants will receive 5-fluorouracil ，400mg/m2，day1 |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2024-05-01
- Completion
- 2026-05-01
- First posted
- 2022-12-07
- Last updated
- 2022-12-07
Source: ClinicalTrials.gov record NCT05640726. Inclusion in this directory is not an endorsement.